Clinical trials: Interferon Deficiency
HTLV-I Infection, Spinal Cord Disease
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body.
- Conditions
- HTLV-I Infection, Spinal Cord Disease, Tropical Spastic Paraparesis
- Trial name
- NCT00001785
- Testing
- Recombinant human interferon beta-1a
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Chronic Granulomatous Disease
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD).
- Trial name
- NCT03548818
- Testing
- Interferon Gamma-1B
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Sarcoma, Kaposi, HIV Infections
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
Primary: To evaluate the safety, toxicity, and antitumor activity of two doses of interferon alfa-2b (IFN-alpha) combined with a fixed dose of didanosine (ddI) in patients with Kaposi's sarcoma associated with HIV infection.
- Trial name
- NCT00001114
- Testing
- Interferon alfa-2b, Didanosine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children
PRIMARY: To determine the safety and toxicity of recombinant interferon gamma-1b ( rIFN-gamma ) in HIV-infected children receiving ongoing zidovudine ( AZT ) or didanosine ( ddI ) therapy.
- Trial name
- NCT00000761
- Testing
- Interferon gamma-1b
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
HIV Infections
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
To evaluate the effects of three preparations of low-dose oral interferon alpha (i.e., Alferon LDO, Veldona, and Ferimmune) on HIV symptoms in HIV-infected patients.
- Trial name
- NCT00000844
- Testing
- Interferon alfa-n3, Interferon alfa-n1
- Where
- 15 sites in United States
- Volunteers
- 560 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sarcoma, Kaposi, HIV Infections
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS.
- Trial name
- NCT00000687
- Testing
- Interferon alfa-2a, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).
- Trial name
- NCT00005012
- Testing
- Peginterferon alfa-2b
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Schering-Plough
HIV Infections
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
To evaluate the anti-HIV effect of single agent versus combination therapy with zidovudine (AZT) and interferon alfa-2a (IFN-A2a), as measured by p24 protein expression, viral growth and infectivity in patients with symptomatic…
- Trial name
- NCT00000696
- Testing
- Interferon alfa-2a, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
Primary: To determine whether the combination of zidovudine/zalcitabine/interferon alfa-n1 (Retrovir/HIVID/Wellferon) can produce complete responses (i.e., CD4 counts return to >= 800 cells/mm3 for more than 24 weeks) in patients…
- Trial name
- NCT00002086
- Testing
- Zidovudine, Zalcitabine, Interferon alfa-n1
- Where
- 13 sites in United States
- Volunteers
- 256 people
- Sponsor
- Glaxo Wellcome
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children
The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well it works to reduce viral load (level of…
- Trial name
- NCT00006325
- Testing
- Peginterferon alfa-2b
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Immunologic Deficiency Syndromes
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
Patients with congenital or acquired immunodeficiencies are at an increased risk to develop polyclonal or oligoclonal lymphoid malignancies.
- Conditions
- HIV Infections, Immunologic Deficiency Syndromes, Lymphoproliferative Disorders
- Trial name
- NCT00001438
- Testing
- all-trans-retinoic acid with IFN-alpha2a
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
To determine the highest tolerated dose of the safety and tolerance of interferon beta (IFN-B) when it is given at the same time as zidovudine (AZT) to patients with early AIDS related Kaposi's sarcoma.
- Trial name
- NCT00000695
- Testing
- Interferon beta-1b, Zidovudine
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leukocyte Adhesion Deficiency Syndrome
Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I
This study will evaluate the safety and effectiveness of the drug, interferon gamma, in treating leukocyte adhesion deficiency type I (LAD I).
- Trial name
- NCT00001905
- Testing
- Interferon gamma
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
In a recent double-blinded, placebo-controlled multi-center international study, subcutaneous injections of interferon-gamma administered three times weekly reduced the frequency of serious infections in patients with chronic…
- Trial name
- NCT00001317
- Testing
- interferon-gamma
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C.
- Trial name
- NCT00001035
- Testing
- Interferon alfa-2b, Zidovudine, Zalcitabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Cryptococcal, HIV Infections
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.
- Trial name
- NCT00012467
- Testing
- Itraconazole, Flucytosine, Fluconazole
- Where
- 9 sites in United States, Peru
- Volunteers
- 60 people
- Sponsor
- InterMune
HIV Infections, Hepatitis C
Treatment of Hepatitis C in Hemophilic Patients With HIV
Pegylated interferon (PEG-interferon) and ribavirin are accepted treatments for hepatitis C virus (HCV) infection. However, HCV infection progresses differently in patients who are coinfected with HIV and in hemophiliacs.
- Conditions
- HIV Infections, Hepatitis C, Hemophilia
- Trial name
- NCT00055341
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis, HIV Infections
Improving Latent Tuberculosis (TB) Diagnosis in Thai Children
The study is a prospective study to improve the diagnosis and management of latent TB in HIV-infected and HIV uninfected children in Thailand.
- Trial name
- TB Px (NCT00947609)
- Where
- 2 sites in Thailand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- SEARCH Research Foundation
HIV Infections
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
PRIMARY: To determine the maximum tolerated dose of interferon-alfa (IFN-A) alone and in combination with zidovudine (AZT); to assess the safety and tolerance of IFN-A alone and in combination with AZT.
- Trial name
- NCT00000967
- Testing
- Interferon alfa-2a, Zidovudine
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)